Cygnus GlucoWatch
This article was originally published in The Gray Sheet
Executive Summary
Co-promotion pact with Sankyo Pharma for U.S. marketing of Cygnus' non-invasive glucose monitoring system gives Cygnus $10 mil. in exchange for a percentage of net sales. The Japanese pharmaceutical firm will leverage its established physician relationships via a 50-person specialty sales force versed in diabetes treatment, 450 primary care sales reps, and 20 managed care account managers to pursue reimbursement. Approved in the U.S. in March, the device is expected to commence a full-scale launch in the first quarter of 2002...